{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-071380","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.020139+00:00","generated_at":"2026-05-17T23:51:33.453048+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Merck reports Q2 2025 sales of $15.8B, down 2%, and announces $3B restructuring program","bullets":["Total worldwide sales $15.8 billion, down 2% nominally and ex-forex vs Q2 2024; KEYTRUDA sales $8.0 billion, up 9%.","GAAP EPS $1.76, Non-GAAP EPS $2.13; includes $0.07 per share charge for Hengrui Pharma license agreement.","GARDASIL/GARDASIL 9 sales $1.1 billion, decline of 55% primarily due to lower demand in China.","Approved 2025 Restructuring Program with cumulative pretax cost ~$3.0 billion, expected annual savings ~$1.7 billion by end of 2027.","Announced agreement to acquire Verona Pharma for ~$10 billion, adding COPD treatment Ohtuvayre; expected close Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-071380","json":"https://secwatch.observer/filing/0001104659-25-071380.json","markdown":"https://secwatch.observer/filing/0001104659-25-071380.md","text":"https://secwatch.observer/filing/0001104659-25-071380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/0001104659-25-071380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T23:51:33.453048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a4228ae83f9f0f174cc51a2befdf1e184f48ba1","claim":"Merck & Co., Inc. announced a restructuring with charges of approximately $3.0 billion affecting sales and administrative organizations, research and development, global real estate footprint, manufacturing network.","evidence_excerpt":"expected to be substantially completed by the end of 2029. The cumulative pretax costs to be incurred by the Company to implement the program are estimated to be approximately $3.0 billion, of which approximately 60% will be cash, relating primarily to employee separation expense and contractual termination costs. The remainder of the costs will be non-cash,","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/0001104659-25-071380-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.0 billion"},{"label":"Affected area","value":"sales and administrative organizations, research and development, global real estate footprint, manufacturing network"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}